$MLTX MERCK will still want this license and pipeline.
It's the only other rival to a very lucrative pipeline that is available. Makes complete sense
I'm in commons with a 6.15 avg and some JAN 2027 30c at 84 cent avg now for a lotto
Nice little bio bounce play trading under cash in hand with license and pipelines and interest from large pharma
Exact same playbook as my $LABP play
$MLTX Comparing To UCB
Analysts compared MoonLake's results to UCB's Bimzelx, an approved treatment for HS.
"Despite the mixed results, SLK appears similar on lesions to BIMZELX, but better on patient reported outcomes, safety and convenience that could still support commercial differentiation with (key opinion leader) support over time," Oppenheimer analyst Andreas Argyrides said in a client note.
He rates MoonLake Immunotherapeutics shares an outperform, but says his model is under review.
But Leerink's Smith notes Bimzelx led to a 15% to 20% improvement over the placebo on the HiSCR75 scale and, in ad hoc testing, was even better at about 22%.
MERCK can now buy this for around 800M-1B at 1/3rd the price they originally offered
Reminds me of my $LABP buy out where AbbVie swopped in and bought Landos, 15x bio trade for me in early 2024
$ITRM
There was a 1 for 10 reverse split in the mix that $LABP did, well before the AbbVie buyout, that skewed these green post percentages a bit, but dammit this is what positive dreams are made of, and why for me StockTwits is so endlessly entertaining.
Some folks can be so so right, and others so um... INCORRECT!
lol
$ITRN
$AMRN $MCRB $LABP
Here comes your next AbbieVie buyout, Steve.
Already have a three month start on the hold, and it's now at a super optimal buy-in price.
$VTGN $LABP $ARDX $MYO Check out $MIRA , they have new drugs for neuropathy, PTSD, depression and dementia. Low float of 15 million and only $1.70 right now.
$GLTO $GLTO don’t focus on price or cash. Anything under $18 (or .70 pre RS) is cheap. Monetization of 1 or both assets has always been the play here. Don’t let the volatility shake you out. The price displacement from recent lows is uncharacteristic and confirms that big operators are here and SA news is imminent. This will be another $LABP imo :)
$GLTO don’t focus on price or cash. Anything under $18 (or .70 pre RS) is cheap. Monetization of 1 or both assets has always been the play here. Don’t let the volatility shake you out. The price displacement from recent lows is uncharacteristic and confirms that big operators are here and SA news is imminent. This will be another $LABP imo :)
@Teambio @lisaparsons Steve got her a 8x buy out on $LABP and now up 50% to my followers on $APPS
Do remember to celebrate my wins aswell as my stocks that are red please :)
$LABP Got my buy out per share $21.40, Not bad from a $4.21 avg and a 9 month hold
All the buy out profits I will be putting into my next candidates $AMRN and $MCRB
https://www.stocktitan.net/news/ABBV/abb-vie-completes-acquisition-of-landos-9mlc83rwf45d.html
